Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis

被引：0

作者：

Sarah Kehr

Philipp Berg

Susanne Müller

Sarah A. Fiedler

Britta Meyer

Gabriele Ruppert-Seipp

Cornelia Witzenhausen

Marc E. Wolf

Hans H. Henkes

Doris Oberle

Brigitte Keller-Stanislawski

Markus B. Funk

机构：

[1] Division Safety of Medicinal Products and Medical Devices,Paul

[2] Klinikum Stuttgart,Ehrlich

[3] Department of Neuroradiology Klinikum Stuttgart,Institut (Federal Institute for Vaccines and Biomedicines)

来源：

npj Vaccines | / 7卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

We present the long-term outcomes of 44 patients who developed cerebral venous sinus thrombosis after vaccination with the adenoviral vector ChAdOx1 nCoV-19 COVID-19 vaccine. Assessment of the Extended Glasgow Outcome Scale was performed within 3–6 months after the initial hospital admissions. Patient outcomes ranged from good recovery (13 patients, 29.6%) to moderate disability (11 patients, 25.0%) and severe disability or vegetative state (6 patients, 13.6%). Fatal outcomes were reported in 14 patients (31.8%).

引用

共 24 条

[1]

Greinacher A(2021)Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination N. Engl. J. Med. 384 2092-2101

[2]

Schultz NH(2021)Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination N. Engl. J. Med. 384 2124-2130

[3]

Scully M(2021)Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination N. Engl. J. Med. 384 2202-2211

[4]

Pavord S(2021)Clinical features of vaccine-induced immune thrombocytopenia and thrombosis N. Engl. J. Med. 385 1680-1689

[5]

Schulz JB(2021)COVID-19 vaccine-associated cerebral venous thrombosis in Germany Ann. Neurol. 90 627-639

[6]

Oldenburg J(2021)Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH Hamostaseologie 41 184-189

[7]

Furie KL(2021)Diagnosis and management of cerebral venous sinus thrombosis with vaccine-induced immune thrombotic thrombocytopenia Stroke 52 2478-2482

[8]

Cushman M(2021)Characteristics and outcomes of patients with cerebral venous sinus thrombosis in SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia JAMA Neurol. 78 1314-1323

[9]

Elkind MSV(2004)Prognosis of cerebral vein and dural sinus thrombosis: results of the international study on cerebral vein and dural sinus thrombosis (ISCVT) Stroke 35 664-670

[10]

Lyden PD(2021)Cerebral vein thrombosis with vaccine-induced immune thrombotic thrombocytopenia Stroke 52 3045-3053

← 1 2 3 →